Mobile

A Phase III, Randomized, Double-blind Study to Evaluate Chemotherapy plus Pembrolizumab vs Chemotherapy plus Placebo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-004740-11

A Phase III, Randomized, Double-blind Study to Evaluate Chemotherapy plus Pembrolizumab vs Chemotherapy plus Placebo as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. To evaluate the rate of pCR using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) as assessed by the local pathologist at the time of definitive surgery in subjects with locally advanced TNBC 2.To evaluate the event-free survival (EFS) as assessed by Investigator in subjects with locally advanced TNBC during the Neoadjuvant and Adjuvant Treatment Phases.

Critère d'inclusion

  • Neoadjuvant and adjuvant treatment for locally-advanced TNBC

Liens